Psilocybin
Rick Doblin Is No Longer MAPS Executive Director. We Didn’t Notice—Did You?
The Multidisciplinary Association for Psychedelic Studies (MAPS) quietly replaced founder Rick Doblin as Executive Director with Kris Lotlikar.
The post…
Rick Doblin Is No Longer MAPS Executive Director. We Didn’t Notice—Did You?
The Multidisciplinary Association for Psychedelic Studies (MAPS) quietly replaced founder Rick Doblin as Executive Director with Kris Lotlikar.
Psymposia is a 501(c)(3) nonprofit research and media organization that offers critical perspectives on drugs, politics, and culture. We rely on contributions from our readers and listeners. Your support is vital to sustaining Psymposia.
Support Psymposia’s independent journalism on Patreon and help us drive the Mystery Machine! We’re a bunch of meddling kids who are unmasking the latest shenanigans on the psychedelics beat.
The Multidisciplinary Association for Psychedelic Studies (MAPS) replaced its longtime Executive Director Rick Doblin at the beginning of the year with an uncharacteristic lack of fanfare.
As of mid-February, Kris Lotlikar assumed Doblin’s role as MAPS’ Executive Director. Prior to this role, Lotlikar co-founded Students for Sensible Drug Policy; energy company Renewable Choice; and Arcview Market Research. He was also a Board member for the Arcview Group—which helped usher capital into the cannabis space.
The transition of Executive Director, from Doblin to Lotlikar, came with no formal announcement from MAPS — an organization generally known for an abundance of psychedelic public relations statements, including an announcement of Doblin’s birthday only months ago.
Rick Doblin’s Tenure
Doblin has been involved in psychedelic drug policy reform efforts for decades, co-founding the organization Earth Metabolic Design Laboratories (EMDL) in 1984 to discourage the Drug Enforcement Agency (DEA) from classifying MDMA as Schedule 1. Following the failed efforts of EMDL, Doblin founded the MAPS nonprofit in 1986 and served as Executive Director until February of this year.
Nearly thirty years after founding the MAPS nonprofit, Doblin announced the creation of a for-profit entity wholly owned by the nonprofit, called MAPS Public Benefit Corporation (MPBC). The MPBC was created to conduct pharmaceutical research and — one day — potentially manufacture and sell MDMA, while the nonprofit remains focused on fundraising.
Under Doblin’s leadership as Executive Director, MAPS raised over $140 million dollars for its psychedelic research, and is currently taking MDMA through Phase 3 trials with the Food and Drug Administration. In many ways, MAPS’ efforts under Doblin have shepherded in the for-profit psychedelic pharmaceutical industry excitement occurring today. Doblin has described industry efforts such as for-profit development of psychedelics like psilocybin as “a sign of the success of [MAPS’] nonprofit work.”
Along with these organizational milestones, MAPS experienced a number of controversies under Doblin’s leadership.
In the early 2000s, journalist Jon Hanna cataloged Doblin’s defense of MAPS-collaborator, John Halpern, who was confronted about his role as a “cooperating witness” for the DEA at a conference in Basel, Switzerland. “Cover Story: Power Trip” — a longform investigation co-produced by Psymposia and New York Magazine — explored a number of abuses and methodological issues which occurred in MAPS’ clinical trials under Doblin’s watch in the 2010s. Doblin’s fellow Board member at MAPS, Vicki Dulai, was recently accused of financial abuse of an elderly MAPS donor. A lawsuit found MAPS’ harm reduction efforts to be liable for the death of a young woman at Lightning in a Bottle. And, just this year, a number of veterans announced feeling used, harmed, and discarded by MAPS and its researchers.
The transition of the MAPS Executive Director position also comes at a time when MAPS appears to be struggling financially. Lucid News reported in March that the nonprofit had, for the “first time offered to sell shares in its for-profit, drug-development subsidiary, MAPS Public Benefit Corporation (MAPS PBC), as it struggles to raise the money needed to bring MDMA to market as a prescription medicine.”
The article notes that this development has been a disappointment for Doblin, “who previously said that MAPS PBC would sell shares only as a last resort.” However, Lucid does imply this decision was made under Doblin’s tenure as Executive Director in 2022. It is unclear how much influence Lotlikar had in this decision, though, at the time, Lotlikar was MAPS President, “overseeing financing and day-to-day operations globally.”
The idea of bringing in outside investors would also be familiar to the former Arcview Board member. Describing the results of Arcview Group’s strategic efforts in the cannabis space, co-founder Steven DeAngelo once said, “Prior to Arcview inviting the investor class in, the movement was driven by people who loved cannabis, but we attracted a lot of people whose motivation was not love of cannabis but love of making money.”
Lotlikar — promoted from MAPS Deputy Director to President between November and December 2022 — now holds Doblin’s former Executive Director position, while Doblin has assumed Lotlikar’s prior role as MAPS President. Why the transition of executive directors was ultimately made so quietly is unclear. Psymposia has reached out to MAPS for comment and will update this story if we receive a response.
The post Rick Doblin Is No Longer MAPS Executive Director. We Didn’t Notice—Did You? appeared first on Psymposia.
psilocybin psychedelics psychedelic mdma fluence research-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Ketamine1 week ago
Clinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd
-
Psychedelics1 week ago
Optimi Health Provides Corporate Update
-
Law & Regulation1 week ago
Horizons talk shifts from investors to insurance
-
Law & Regulation1 week ago
DEA psychedelics ban hearing halted by lawsuit
-
Law & Regulation5 days ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics4 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001